CliffBio
small molecule

ASMANEX TWISTHALER

MOMETASONE FUROATE

Loss of exclusivity—loss of exclusivity
CompanyOrganon →See this company's full patent-cliff portfolio

Drug detail

Brand nameASMANEX TWISTHALER
Active ingredientMOMETASONE FUROATE
Strength0.11MG/INH
Dosage formPOWDER
RouteINHALATION
ModalitySmall molecule
FDA approvalFebruary 2008
Marketing statusRX

More from Organon

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

ASMANEX TWISTHALER patent cliff — loss of exclusivity — | CliffBio